Pulmotect is pioneering an immunomodulatory and “pathogen agnostic” approach to preventing and treating respiratory complications by harnessing the power of the innate immune system. We are advancing our lead program, PUL-042, a first in class, patent protected, inhaled therapy that activates the innate immunity of the lungs. We are focused on improving outcomes in high-risk populations including immunosuppressed oncology patients at risk of complications from respiratory infection. The development of our strategy is supported by remarkable pre-clinical data and positive data from our Phase 1 and Phase 2 studies with PUL-042. Check out our pipeline to learn more.